MedTrace Logo

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

NCT05001282 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2024-08-07

No results posted yet for this study

Summary

This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available.

Conditions

  • Ovarian Cancer
  • Ovarian Neoplasms
  • Ovarian Carcinoma
  • Endometrial Cancer
  • Ovary Cancer
  • Ovary Neoplasm
  • Ovary Disease
  • Ovary Metastasis
  • Ovarian Diseases
  • Ovarian Cancer Stage
  • Ovarian Epithelial Cancer
  • Ovarian Adenocarcinoma
  • Ovarian Serous Adenocarcinoma
  • Ovarian Neoplasm Epithelial
  • Ovarian Cancer Recurrent
  • Endometrial Diseases
  • Endometrial Adenocarcinoma
  • Endometrial Carcinosarcoma
  • Endometrial Clear Cell Adenocarcinoma
  • Endometrioid Adenocarcinoma
  • Endometrial Neoplasms
  • Endometrial Cancer Recurrent
  • Endometrioid Tumor
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Interventions

DRUG

ELU001

Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)

Sponsors & Collaborators

  • Elucida Oncology

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-13
Primary Completion
2024-06-07
Completion
2024-06-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05001282 on ClinicalTrials.gov